期刊
CELL REPORTS MEDICINE
卷 2, 期 12, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.xcrm.2021.100455
关键词
-
资金
- Dr. JohnR. and Clara M. Fraser Memorial Trust
- Terry Fox Foundation
- Quebec Breast Cancer Foundation
- Goodman Cancer Research Center
- McGill University
Engineered mesenchymal stromal cells (MSC-IPr) exhibit enhanced antigen cross-presentation abilities, leading to potent re-activation of T cell immunity and effective control of tumor growth. The combination with antibodies further enhances the effect, making them suitable for designing universal cell-based cancer vaccines.
Dendritic cells (DCs) excel at cross-presenting antigens, but their effectiveness as cancer vaccine is limited. Here, we describe a vaccination approach using mesenchymal stromal cells (MSCs) engineered to express the immunoproteasome complex (MSC-IPr). Such modification instills efficient antigen cross-presentation abilities associated with enhanced major histocompatibility complex class I and CD80 expression, de novo production of interleukin-12, and higher chemokine secretion. This cross-presentation capacity of MSC-IPr is highly dependent on their metabolic activity. Compared with DCs, MSC-IPr hold the ability to cross-present a vastly different epitope repertoire, which translates into potent re-activation of T cell immunity against EL4 and A20 lymphomas and B16 melanoma tumors. Moreover, therapeutic vaccination of mice with pre-established tumors efficiently controls cancer growth, an effect further enhanced when combined with antibodies targeting PD-1, CTLA4, LAG3, or 4-1BB under both autologous and allogeneic settings. Therefore, MSC-IPr constitute a promising subset of non-hematopoietic antigen-presenting cells suitable for designing universal cell-based cancer vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据